FY2025 Earnings Forecast for KYTX Issued By Leerink Partnrs

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings per share (EPS) estimates for Kyverna Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($4.20) for the year, up from their prior forecast of ($4.35). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($4.66) EPS and FY2028 earnings at ($4.85) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last released its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.01. The firm had revenue of $0.01 million during the quarter.

Other research analysts have also issued research reports about the company. HC Wainwright dropped their target price on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. Wells Fargo & Company dropped their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, November 15th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kyverna Therapeutics presently has a consensus rating of “Buy” and an average price target of $25.71.

Kyverna Therapeutics Trading Down 2.7 %

Shares of NASDAQ:KYTX opened at $2.93 on Monday. Kyverna Therapeutics has a 12 month low of $2.91 and a 12 month high of $30.60. The firm’s 50-day moving average is $3.79 and its 200 day moving average is $5.31.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KYTX. FMR LLC purchased a new position in shares of Kyverna Therapeutics during the third quarter valued at $33,000. China Universal Asset Management Co. Ltd. bought a new position in Kyverna Therapeutics during the 4th quarter worth about $34,000. Creative Planning purchased a new position in Kyverna Therapeutics during the 3rd quarter valued at about $54,000. Corebridge Financial Inc. raised its holdings in shares of Kyverna Therapeutics by 42.3% in the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company’s stock valued at $48,000 after purchasing an additional 3,810 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Kyverna Therapeutics in the 3rd quarter worth approximately $97,000. 18.08% of the stock is owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.